Martina Vrankar (Author), Karmen Stanič (Author)

Abstract

Standard treatment for patients with inoperable locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT). Five-year overall survival rates range between 15 and 25%, while long term survival data are rarely reported. Patients and methods A total of 102 patients with stage III NSCLC treated between September 2005 and November 2010 with induction chemotherapy and CCRT were included in this long term survival analysis. All patients were tested for PD-L1 status and expression of PD-L1 was correlated with overall survival (OS), progression free survival (PFS) and toxicities. Results The median OS of all patients was 24.8 months (95% CI 18.7 to 31.0) with 10 year-survival rate of 11.2%. The median OS of patients with PD-L1 expression was 12.1 months (95% CI 0.1 to 26.2), while in patients with negative or unknown PD-L1 status was significantly longer, 25.2 months (95% CI 18.9 to 31.6), p = 0.005. The median PFS of all patients was 16.4 months (95% CI 13.0 to 19.9). PFS of patients with PD-L1 expression was 10.1 months (95% CI 0.1 to 20.4) and in patients with negative or unknown PD-L1 status was 17.9 months (95% CI 14.2 to 21.7), p = 0.003. Conclusions 10-year overall survival of stage III NSCLC patients after CCRT is 11.2%. PFS and OS differ with regard to PD-L1 status and are significantly shorter for patients with PD-L1 expression. New treatment with check-point inhibitors combined with RT therefore seems reasonable strategy to improve these results.

Keywords

NSCLC;non-small cell lung cancer;locally advanced;immunotherapy;chemoradiotherapy;

Data

Language: English
Year of publishing:
Typology: 1.01 - Original Scientific Article
Organization: OI - Institute of Oncology
Publisher: Association of Radiology and Oncology
UDC: 616.2
COBISS: 2855035 Link will open in a new window
ISSN: 1318-2099
Views: 27
Downloads: 19
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: Slovenian
Secondary keywords: nedrobnocelični rak pljuč;lokalno napredovali rak pljuč;kemoradioterapija;imunoterapija;
Pages: str. 281-288, IV
Volume: ǂVol. ǂ52
Issue: ǂno. ǂ3
Chronology: Sep. 2018
DOI: 10.1515/raon-2018-0009
ID: 24168191